At the news
? BEARISHIMPACT 5/10 424B5 filed Nov 6, 2026 at 16:30 ET
Inovio Pharmaceuticals priced a $75.0M underwritten offering of 58.7M common shares and pre-funded warrants at $1.05 per share, a 27.6% discount to the $1.45 last reported sale price. The offering follows the October 30 FDA accelerated approval of VOCERYQ and the company's disclosure of only $48.4M in cash, with a going concern warning. Proceeds will fund the VOCERYQ commercial launch and pipeline development, but the massive dilution (53% of pre-offering shares outstanding) and deep discount signal acute capital needs at a $168M market cap.
- 58,747,235 common shares and pre-funded warrants for 12,681,337 shares offered at $1.05 per share
- Offering price is a 27.6% discount to the $1.45 last reported sale price on November 5, 2026
- Total gross proceeds of approximately $75.0M; net proceeds estimated at $70.0M
- Shares outstanding will increase from 110.2M to 168.9M (53% dilution) excluding pre-funded warrants
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access